The present invention relates to an amorphous form of vilazodone hydrochloride and processes for the preparation of amorphous form of vilazodone hydrochloride. The present invention also relates to pharmaceutical compositions that include a therapeutically effective amount of the amorphous form of vilazodone hydrochloride and use of said compositions for the treatment of major depressive disorder (MDD).